Yara Abdou: Our ASCO editorial on assessing target expression for ADC efficacy
Yara Abdou, Assistant Professor at the University of North Carolina, shared a post by ASCO on X, adding:
“Check out our ASCO editorial on assessing target expression for ADC efficacy, would love to hear your thoughts on this topic as well! ”
Quoting ASCO‘s post:
“Though ADCs have emerged as a cutting-edge approach to chemotherapy, determining when and how to assess targets in pts with metastatic Breast Cancer remains an evolving challenge.
Yara Abdou and Paola Zagami discuss in a new editorial for ASCODaily News.”
Yara Abdou, MD, is an Assistant Professor at the University of North Carolina at Chapel Hill specializing in early-stage and metastatic breast cancer. Her research centers on developing targeted immunotherapies to treat diverse breast cancer subtypes, with a focus on understanding racial differences in tumor biology and the immune microenvironment. Working with basic and translational scientists, she aims to improve treatment efficacy and address disparities in outcomes for minority women with breast cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023